Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy.
- Author:
Hai-xiang SONG
1
;
Jing GONG
;
Wen CHEN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Chemokine CCL2; urine; Diabetic Nephropathies; drug therapy; urine; Diterpenes; therapeutic use; Epoxy Compounds; Female; Humans; Immunosuppressive Agents; therapeutic use; Male; Middle Aged; Phenanthrenes; therapeutic use; Phytotherapy; Prospective Studies
- From: Chinese Journal of Integrated Traditional and Western Medicine 2005;25(5):416-418
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the change of urinary monocyte chemottractant protein-1 (MCP-1) in patients with diabetic nephropathy (DN), and to explore the therapeutic effect and mechanism of triptolide (TL) in treating DN.
METHODSThirty-five patients in the treated group were treated with TL plus benazepril and thirty two patients in the control group were treated with benazepril alone for six months. The change of urinary MCP-1 was measured before and after treatment.
RESULTSLevel of urinary MCP-1 in DN patients was significantly higher than that in healthy subjects (P < 0.01), but it could be significantly decreased after TL treatment, showing significant difference as compared with that in the control group (P < 0.05).
CONCLUSIONDetermination of urinary MCP-1 level is beneficial to know the degree of kidney inflammation in DN patients. TL can inhibit inflammatory reaction to decrease the level of urinary MCP-1, and thus improve the renal function.
